Ground-breaking Research Made Possible by Exemplar Genetics
The latest disease model from Exemplar Genetics, a company committed to enabling research into life-threatening human diseases, is featured in the current issue of PLOS ONE magazine.
Exemplar Genetics will be a sponsor at Livestock Biotech Summit September 16-18
September 16-18, 2014, Sioux Falls, South Dakota Conference Website
Visit Exemplar Genetics at AALAS 65th National Meeting in San Antonio, TX October 19–23, 2014
AALAS 65th National Meeting San Antonio, TX Booth #1645 October 19–23, 2014 Convention Website
Stop by to see Exemplar Genetics at American Heart Association Scientific Sessions November 15-19
Nov 15-19, 2014 McCormick Place Chicago, IL Booth #1013 Convention Website
ExeGen LDLR MiniSwine
Features consistent, stable hypercholesterolemia that can be further modulated by diet. Predictable, progressive atherosclerosis that manifests on an accelerated timeline. Atherosclerotic lesion formation in the aorta and coronary arteries that model key pathophysiological aspects of human atherosclerosis. Defined Yucatan miniature swine genetics that offers greater consistency.
A rare opportunity arises for an family fighting a rare disease
“You could have picked me up off of the floor. Out of 50,000 people at a conference, the chances of meeting someone researching A-T is very, very rare. Dr. Swart never could have imagined that I was connected to the organization or a mother of three A-T adults. I told him that maybe I could help,” Amy said, laughing.
Discovery drives the human race to new heights each day.
Explorers in all fields have made our lives and world better through their courage to venture into new frontiers and beyond. Yet, their ability to discover has always relied on the proper vehicle to propel them from theory to reality. At Exemplar Genetics, we enable discovery by providing the vehicle to break new ground on the medical research frontier.
Until now, researchers have lacked animal models that faithfully represent human diseases. As a result, a sizeable barrier has blocked progress in the discovery of human disease mechanisms; novel diagnostics, procedures, devices, prevention strategies and therapeutics; and the ability to predict in humans the efficacy of those next-generation procedures, devices, and therapeutics.